Herein we focus primarily on the significant metabolic targets associated with Danshen, including c-Jun N-terminal kinases (JNKs), SREBP-1c, ChREBP, PPARs, CYPs and the others, to provide theoretical basis for the development of a new way of Danshen treatment of NAFLD. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.